Eton Pharmaceuticals (ETON) News
NASDAQ: ETONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
60.85-0.51 (-0.83%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ETON news summary
We found 10 recent headlines mentioning Eton Pharmaceuticals (ETON): 2 in the past week and 8 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, ETON is down 0.83% at $60.85. The most recent story, "REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Eton Pharmaceuticals headlines
- REGN Gets FDA Nod for Livsayis in Generalized Myasthenia GravisRegeneron's Livsayis becomes the first and only siRNA therapy approved by the FDA for generalized myasthenia gravis, offering four subcutaneous doses a year.NasdaqREGN, ALNY, VCEL, ETON
- NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia RheumaticaNovartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.NasdaqNVS, VCEL, ETON
- Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study ResultsOn November 5, 2026, Eton Pharmaceuticals, Inc. issued a press release announcing preliminary results from a randomized, double-blind, placebo-controlled pilot study evaluating ET-700, its…Nasdaq
- Eton Pharmaceuticals Reports Third Quarter 2026 Financial ResultsDEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…GlobeNewswire
- Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in LondonDEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…GlobeNewswire
- ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.NasdaqETON, TGTX, IOVA, AMRX
- Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic SpasmsDEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…GlobeNewswire
- Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…GlobeNewswire
- Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmDEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…GlobeNewswireETON, AQST
- ETON Stock Surges 108% in Six Months: Here's What You Need to KnowEton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.NasdaqETON, ALNY, AMRN, ALDX